NewGenIVF Announces Reverse Stock Split
NewGenIVF Group Limited (NASDAQ: NIVF), an Asian fertility services provider, has announced a 1-for-10 reverse stock split effective May 5, 2025. The reverse split will reduce outstanding Class A Ordinary Shares from 7,302,819 to approximately 730,282 shares. The company will continue trading under the symbol "NIVF" on the Nasdaq Global Market with a new CUSIP number G0544E121.
No fractional shares will be issued - shareholders entitled to fractional shares will receive one full post-split share instead. All outstanding options, warrants, and convertible securities will be proportionally adjusted by dividing the number of shares by ten, subject to rounding to the nearest whole share.
NewGenIVF Group Limited (NASDAQ: NIVF), un fornitore asiatico di servizi per la fertilità, ha annunciato un raggruppamento azionario inverso 1-per-10 con effetto dal 5 maggio 2025. Il raggruppamento ridurrà le azioni ordinarie di Classe A in circolazione da 7.302.819 a circa 730.282 azioni. La società continuerà a essere quotata con il simbolo "NIVF" sul Nasdaq Global Market con un nuovo numero CUSIP G0544E121.
Non saranno emesse azioni frazionarie: gli azionisti aventi diritto a frazioni di azioni riceveranno invece una azione intera dopo il raggruppamento. Tutte le opzioni, i warrant e i titoli convertibili in circolazione saranno adeguati proporzionalmente dividendo il numero di azioni per dieci, con arrotondamento all'azione intera più vicina.
NewGenIVF Group Limited (NASDAQ: NIVF), un proveedor asiático de servicios de fertilidad, ha anunciado una consolidación inversa de acciones 1 por 10 con efecto a partir del 5 de mayo de 2025. La consolidación reducirá las acciones ordinarias Clase A en circulación de 7,302,819 a aproximadamente 730,282 acciones. La compañía continuará cotizando bajo el símbolo "NIVF" en el Nasdaq Global Market con un nuevo número CUSIP G0544E121.
No se emitirán acciones fraccionarias: los accionistas que tengan derecho a acciones fraccionarias recibirán una acción completa después de la consolidación. Todas las opciones, warrants y valores convertibles en circulación se ajustarán proporcionalmente dividiendo el número de acciones por diez, con redondeo al número entero más cercano.
NewGenIVF Group Limited (NASDAQ: NIVF)는 아시아의 생식 서비스 제공업체로서, 2025년 5월 5일부터 1대 10 역병합 주식 분할을 시행한다고 발표했습니다. 이번 역병합으로 기존의 클래스 A 보통주 7,302,819주가 약 730,282주로 줄어듭니다. 회사는 나스닥 글로벌 마켓에서 "NIVF" 심볼로 계속 거래되며, 새로운 CUSIP 번호는 G0544E121입니다.
분할 후 소수 주식은 발행되지 않으며, 소수 주식 권리가 있는 주주는 대신 1주 전체 주식을 받게 됩니다. 모든 미결제 옵션, 워런트, 전환증권은 주식 수를 10으로 나누어 비례 조정되며, 가장 가까운 정수로 반올림됩니다.
NewGenIVF Group Limited (NASDAQ : NIVF), un fournisseur asiatique de services en fertilité, a annoncé une division inversée d'actions au ratio de 1 pour 10 effective à compter du 5 mai 2025. Cette opération réduira les actions ordinaires de Classe A en circulation de 7 302 819 à environ 730 282 actions. La société continuera de négocier sous le symbole "NIVF" sur le Nasdaq Global Market avec un nouveau numéro CUSIP G0544E121.
Aucune action fractionnaire ne sera émise – les actionnaires ayant droit à des fractions d’actions recevront une action entière après la division. Toutes les options, bons de souscription et titres convertibles en circulation seront ajustés proportionnellement en divisant le nombre d’actions par dix, avec un arrondi à l’action entière la plus proche.
NewGenIVF Group Limited (NASDAQ: NIVF), ein asiatischer Anbieter von Fruchtbarkeitsdiensten, hat eine 1-zu-10 Reverse-Aktienzusammenlegung mit Wirkung zum 5. Mai 2025 angekündigt. Die Zusammenlegung reduziert die ausstehenden Stammaktien der Klasse A von 7.302.819 auf etwa 730.282 Aktien. Das Unternehmen wird weiterhin unter dem Symbol "NIVF" am Nasdaq Global Market gehandelt und erhält eine neue CUSIP-Nummer G0544E121.
Bruchstücke von Aktien werden nicht ausgegeben – Aktionäre, die Anspruch auf Bruchstücke haben, erhalten stattdessen je eine ganze Aktie nach der Zusammenlegung. Alle ausstehenden Optionen, Warrants und wandelbaren Wertpapiere werden proportional angepasst, indem die Anzahl der Aktien durch zehn geteilt wird, wobei auf die nächste ganze Aktie gerundet wird.
- Potential to maintain Nasdaq listing compliance through higher share price
- Reduced number of shares outstanding could make the stock more attractive to institutional investors
- Reverse splits are often viewed negatively by the market as a sign of company distress
- No fundamental change to company value or market capitalization
Insights
NewGenIVF's 1:10 reverse split reduces share count without changing total company value, a technical adjustment affecting share structure only.
NewGenIVF has announced a 1-for-10 reverse stock split effective May 5, 2025. This technical adjustment will reduce the company's outstanding Class A Ordinary Shares from 7,302,819 to approximately 730,282 shares. For shareholders, this means every 10 shares currently owned will be consolidated into 1 share.
A reverse stock split is a mechanical procedure that consolidates a company's outstanding shares without changing its overall market capitalization (total company value). While each share will represent a larger percentage of ownership, an investor's total percentage ownership in the company remains unchanged.
The company has stated that no fractional shares will be issued. Instead, shareholders entitled to fractional shares will receive one full post-split share, which is slightly beneficial to smaller shareholders.
Additionally, all outstanding options, warrants, and convertible securities will be proportionally adjusted by the same 1:10 ratio, maintaining their relative value and preventing dilution or enrichment of those security holders.
The stock will continue trading under the same ticker symbol "NIVF" but will receive a new CUSIP number (G0544E121), which is a standard procedure for corporate actions of this nature. This identifier change helps market participants track the security correctly after structural modifications.
This corporate action represents a technical adjustment to NewGenIVF's capital structure rather than a fundamental change to its business operations or financial performance.
BANGKOK, May 01, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced that it is implementing a reverse stock split of all of the Company's issued and unissued shares at an exchange ratio of one (1) share for ten (10) shares (the “Reverse Stock Split”).
The Company’s Class A Ordinary Shares will begin trading on the Nasdaq Global Market on a post-Reverse Stock Split basis under the current ticker symbol “NIVF” at the commencement of trading on May 5, 2025, under the new CUSIP number G0544E121.
The Reverse Stock Split will reduce the number of outstanding Class A Ordinary Shares of the Company from 7,302,819 to approximately 730,282 Class A Ordinary Shares. Every ten (10) outstanding Class A Ordinary Shares will be combined into and automatically become one post-Reverse Stock Split Class A Ordinary Share. No fractional shares will be issued in connection with the Reverse Stock Split. Instead, the Company will issue one full post-Reverse Stock Split Class A Ordinary Share to any shareholder at a participant level who would have been entitled to receive a fractional share as a result of the process.
After the Reverse Stock Split, all options, warrants and other convertible securities of the Company outstanding immediately prior to the Reverse Stock Split will be adjusted by dividing the number of Class A Ordinary Shares into which the options, warrants and other convertible securities are exercisable or convertible by ten (10) in accordance with the terms of the plans, agreements or arrangements governing such options, warrants and other convertible securities and subject to rounding to the nearest whole share.
About NewGen
NewGen is a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments. With a mission to aid couples and individuals in building families regardless of fertility challenges, NewGen has dedicated itself to creating increased access to infertility treatment and providing comprehensive fertility services for its customers. NewGen’s management team collectively has over a decade of experience in the fertility industry. NewGen’s clinics are located in Thailand, Cambodia, and Kyrgyzstan, and present a full suite of services for its patients, including comprehensive infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, in the appropriate jurisdictions, respectively. To learn more, visit www.newgenivf.com. The information contained on, or accessible through, NewGen’s website is not incorporated by reference into this press release, and you should not consider it a part of this press release.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations, business strategy, and financial condition. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, the Company’s inability to meet or exceed its financial projections, or changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the Company’s annual report on Form 20-F and other documents filed or to be filed by the Company with the SEC from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC’s website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
Investor Relations Contact
ICR, LLC
Robin Yang
Phone: +1 (212) 537-4406
Email: Newgenivf.IR@icrinc.com
FAQ
What is the reverse stock split ratio for NIVF stock?
How many shares will NIVF have outstanding after the reverse split?
When will NIVF's reverse stock split take effect?
How will NIVF handle fractional shares in the reverse split?
What happens to NIVF options and warrants after the reverse split?
